Article Text

Download PDFPDF
Original research
System-level trends in ischemic stroke admissions after adding endovascular stroke capabilities in community hospitals
  1. Prateek Kumar1,
  2. Sergio Salazar-Marioni1,
  3. Saagar Dhanjani2,
  4. Ananya Iyyangar1,
  5. Rania Abdelkhaleq1,
  6. Muhammad Bilal Tariq1,
  7. Arash Niktabe1,
  8. Anjan N Ballekere1,
  9. Ngoc Mai Le1,
  10. Hussain Azeem1,
  11. Louise McCullough1,
  12. Sunil A Sheth1,
  13. Eunyoung Lee1
    1. 1Department of Neurology, McGovern Medical School at UTHealth, Houston, Texas, USA
    2. 2Rice University, Houston, Texas, USA
    1. Correspondence to Dr Sunil A Sheth; Sunil.A.Sheth{at}uth.tmc.edu

    Abstract

    Background There is substantial interest in adding endovascular stroke therapy (EST) capabilities in community hospitals. Here, we assess the effect of transitioning to an EST-performing hospital (EPH) on acute ischemic stroke (AIS) admissions in a large hospital system including academic and community hospitals.

    Methods From our prospectively collected multi-institutional registry, we collected data on AIS admissions at 10 hospitals in the greater Houston area from January 2014 to December 2022: one longstanding EPH (group A), three community hospitals that transitioned to EPHs in November 2017 (group B), and six community non-EPHs that remained non-EPH (group C). Primary outcomes were trends in total AIS admissions, large vessel occlusion (LVO) and non-LVO AIS, and tissue plasminogen activator (tPA) and EST use.

    Results Among 20 317 AIS admissions, median age was 67 (IQR 57–77) years, 52.4% were male, and median National Institutes of Health Stroke Scale (NIHSS) was 4 (IQR 1–10). During the first 12 months after EPH transition, AIS admissions increased by 1.9% per month for group B, with non-LVO stroke increasing by 4.2% per month (P<0.001). A significant change occurred for group A at the transition point for all outcomes with decreasing rates in admissions for AIS, non-LVO AIS and LVO AIS, and decreasing rates of EST and tPA treatments (P<0.001).

    Conclusion Upgrading to EPH status was associated with a 2% per month increase in AIS admissions during the first year post-transition for the upgrading hospitals, but decreasing volumes and treatments at the established EPH. These findings quantify the impact on AIS admissions in hospital systems with increasing EST access in community hospitals.

    • Stroke
    • Intervention
    • Political

    Data availability statement

    Data are available upon reasonable request.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request.

    View Full Text

    Footnotes

    • X @BilalTariq_MD

    • Contributors The following authors were responsible for data collection, analysis, manuscript preparation and revision: PK, SS-M, SD, AI, RA, MBT, AN, ANB, ML, HA, LM, SAS, EL. SAS is also the guarantor of this work.

    • Funding This study was funded by National Institute of Neurological Disorders and Stroke (R01NS121154).

    • Competing interests SAS reports funding from the National Institutes of Health as well as consultancy fees from Penumbra, Viz.AI and Imperative Care for unrelated topics.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.